Home > Publications database > Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study. > print

001     292457
005     20240919150643.0
024 7 _ |a 10.1093/jncics/pkae070
|2 doi
024 7 _ |a pmid:39180334
|2 pmid
024 7 _ |a altmetric:166701745
|2 altmetric
037 _ _ |a DKFZ-2024-01724
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Cariolou, Margarita
|b 0
245 _ _ |a Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.
260 _ _ |a Oxford
|c 2024
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726751163_16238
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Sep 2;8(5):pkae070
520 _ _ |a Adiposity has been characterised as a modifiable risk factor of prostate cancer. Its association with outcomes after prostate cancer diagnosis, however, needs to be better understood and obtain more evidence to assist the development of lifestyle guidance for prostate cancer patients.We investigated the associations between adiposity indices close to prostate cancer diagnosis (up to two years pre- or up to five years post-diagnosis) and mortality in 1,968 men of the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Men were followed for a median of 9.5 years. Cox proportional-hazards models were adjusted for age and year of diagnosis, stage, grade, smoking and stratified by country.Each 5-unit increment in pre- or post-diagnosis body mass index (BMI) combined was associated with a 30% higher rate of all-cause and a 49% higher rate of prostate cancer-specific mortality. Similarly, each 5-unit increment in pre-diagnosis BMI was associated with a 35% higher rate of all-cause and a 51% higher rate of prostate cancer-specific mortality. The associations were less strong for post-diagnosis BMI with a lower number of men in analyses. Less clear positive associations were shown for waist circumference, hip circumference, and waist-to-hip ratio but data was limited.Elevated levels of adiposity close to prostate cancer diagnosis could lead to higher risk of mortality; therefore, men are encouraged to maintain a healthy weight. Additional research is needed to confirm if excessive adiposity after prostate cancer diagnosis could worsen prognosis.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a adiposity
|2 Other
650 _ 7 |a lifestyle
|2 Other
650 _ 7 |a mortality
|2 Other
650 _ 7 |a prostate cancer
|2 Other
650 _ 7 |a survival
|2 Other
700 1 _ |a Christakoudi, Sofia
|b 1
700 1 _ |a Gunter, Marc J
|b 2
700 1 _ |a Key, Tim
|b 3
700 1 _ |a Pérez-Cornago, Aurora
|b 4
700 1 _ |a Travis, Ruth
|b 5
700 1 _ |a Zamora-Ros, Raul
|b 6
700 1 _ |a Petersen, Kristina Elin T
|b 7
700 1 _ |a Tjønneland, Anne
|b 8
700 1 _ |a Weiderpass, Elisabete
|b 9
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 10
|u dkfz
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 11
|u dkfz
700 1 _ |a Inan-Eroglu, Elif
|b 12
700 1 _ |a Schulze, Matthias B
|b 13
700 1 _ |a Masala, Giovanna
|b 14
700 1 _ |a Agnoli, Claudia
|b 15
700 1 _ |a Tumino, Rosario
|b 16
700 1 _ |a Di Girolamo, Chiara
|b 17
700 1 _ |a Aizpurua, Amaia
|b 18
700 1 _ |a Rodriguez-Barranco, Miguel
|b 19
700 1 _ |a Santiuste, Carmen
|b 20
700 1 _ |a Guevara, Marcela
|b 21
700 1 _ |a Aune, Dagfinn
|b 22
700 1 _ |a Chan, Doris Sm
|b 23
700 1 _ |a Muller, David C
|b 24
700 1 _ |a Tsilidis, Konstantinos K
|b 25
773 _ _ |a 10.1093/jncics/pkae070
|g p. pkae070
|0 PERI:(DE-600)2975772-1
|n 5
|p pkae070
|t JNCI cancer spectrum
|v 8
|y 2024
|x 2515-5091
909 C O |p VDB
|o oai:inrepo02.dkfz.de:292457
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JNCI CANCER SPECT : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-22T16:36:51Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-22T16:36:51Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2022-09-22T16:36:51Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21